The American Cancer Society, the Association of Clinical Oncology, and the American Association for Cancer Research are calling on the Centers for Disease Control and Prevention to give cancer patients a higher priority amid the rollout of vaccines against SARS-CoV-2.
Cancer patients and survivors should not get COVID-19. A three-time cancer survivor should definitely not get COVID. But I did. And it was not good. Here is my story and the lessons I learned that might be of value to others.
Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs.
The year 2020 was, by any reckoning, one that most of us would prefer to relegate to history books—fun to read about, and hopefully not condemned to repeat.
Historical documents have a way of vanishing. Manuscripts, letters, and photographs end up in city dumps. Memories become less granular, insight is lost. The documents that do get preserved often require a trip to the archives.
President Donald Trump is hardly the first septuagenarian world leader to mistrust doctors and science.
During my 30-year career in health care, I've worked with hundreds of community oncology practices. Most oncologists I've worked with have, for quite some time, intuitively understood that social determinants of health (SDOH) can significantly impact patient outcomes.
Keytruda (pembrolizumab) received accelerated approval from FDA in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test.
FDA has issued a Draft Guidance for comment describing the agency's proposed recommendations for including relevant information about oncology drug labels that have been approved for use in combination drug regimens.
The Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research at FDA plan to take additional steps to increase transparency regarding CDER and CBER's review of the scientific information supporting the issuance of or revisions to an emergency use authorizations.
